ReviewPharmacological reports : PR2015
A new paradigm for XOR-catalyzed reactive species generation in the endothelium.
Review in Pharmacological reports : PR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Tart cherry intake and serum uric acid: Meta-analysis of randomized controlled trials and evidence from network pharmacology.Asia Pacific journal of clinical nutrition · 2026Pooled it
- Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study.Obesity facts · 2024Trial
- Inhalation exposure to surrogate military burn pit emissions impairs systemic microvascular function: linking pulmonary insult and diverse peripheral responses.Particle and fibre toxicology · 2026Article
- Nitrite supplementation alleviates cerebrovascular dysfunction in chronically stressed mice, but cognitive decline remains.Experimental physiology · 2026Article
- Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan - A JMDC Claims Database Study.Circulation reports · 2025Article
- Gender Influence on XOR Activities and Related Pathologies: A Narrative Review.Antioxidants (Basel, Switzerland) · 2024Review
- Mitochondrial Dysfunction in Endothelial Progenitor Cells: Unraveling Insights from Vascular Endothelial Cells.Biology · 2024Review
- Comprehensive analysis of the relationship between xanthine oxidoreductase activity and chronic kidney disease.iScience · 2023Article
- A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases.Biomedicines · 2023Article
- Indirect Antioxidant Effects of the Nitrite Anion: Focus on Xanthine Oxidase.Advances in redox research · 2023Article
- Article
- The double faced role of xanthine oxidoreductase in cancer.Acta pharmacologica Sinica · 2022Review
- A physiologically relevant role for NO stored in vascular smooth muscle cells: A novel theory of vascular NO signaling.Redox biology · 2022Review
- U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.Redox biology · 2022Review
- Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Antioxidant Molecules Isolated from Edible Prostrate Knotweed: Rational Derivatization to Produce More Potent Molecules.Oxidative medicine and cellular longevity · 2022Article
- Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation.JCI insight · 2021Article
- Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.Journal of diabetes investigation · 2021Article
- Plasma Xanthine Oxidoreductase Activity Is Associated with a High Risk of Cardiovascular Disease in a General Japanese Population.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
A plethora of vascular pathology is associated with inflammation, hypoxia and elevated rates of reactive species generation. A critical source of these reactive species is the purine catabolizing enzyme xanthine oxidoreductase (XOR) as numerous reports over the past 30 years have demonstrated XOR inhibition to be salutary. Despite this long standing association between increased vascular XOR activity and negative clinical outcomes, recent reports reveal a new paradigm whereby the enzymatic activity of XOR mediates beneficial outcomes by catalyzing the one electron reduction of nitrite (NO2(-)) to nitric oxide (NO) when NO2(-) and/or nitrate (NO3(-)) levels are enhanced either via dietary or pharmacologic means. These observations seemingly countervail numerous reports of improved outcomes in similar models upon XOR inhibition in the absence of NO2(-) treatment affirming the need for a more clear understanding of the mechanisms underpinning the product identity of XOR. To establish the micro-environmental conditions requisite for in vivo XOR-catalyzed oxidant and NO production, this review assesses the impact of pH, O2 tension, enzyme-endothelial interactions, substrate concentrations and catalytic differences between xanthine oxidase (XO) and xanthine dehydrogenase (XDH). As such, it reveals critical information necessary to distinguish if pursuit of NO2(-) supplementation will afford greater benefit than inhibition strategies and thus enhance the efficacy of current approaches to treat vascular pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.